

Pharmacy Services

(800) 522-0114, option 4

November 11, 2017

Dear SoonerCare Provider,

The purpose of this fax is to provide information regarding criteria recently established for the reimbursement of Aczone[®] (Dapsone Gel 7.5) and Tazorac[®] (Tazarotene Cream and Gel). You are receiving this fax because you recently prescribed or dispensed Aczone[®] or Tazorac[®] for SoonerCare member(s). Effective December 4, 2017, Aczone[®] (Dapsone Gel 7.5) and Tazorac[®] (Tazarotene Cream and Gel) will require prior authorization. The authorization criteria for reimbursement is as follows:

Aczone® (Dapsone Gel 7.5) Approval Criteria:

- 1. An FDA approved indication of acne vulgaris; and
- 2. Member must be 20 years of age or younger; and
- 3. A previous trial of benzoyl peroxide or a patient-specific, clinically significant reason why benzoyl peroxide is not appropriate for the member; and
- 4. A previous trial of a topical antibiotic, such as clindamycin or erythromycin, or a patientspecific, clinically significant reason why a topical antibiotic is not appropriate for the member.

Tazorac[®] (Tazarotene Cream and Gel) Approval Criteria:

- 1. An FDA approved indication of acne vulgaris or plaque psoriasis; and
- 2. Female members must not be pregnant and must be willing to use an effective method of contraception during treatment; and
- 3. Authorization of generic tazarotene (in place of brand Tazorac[®]) will require a patient-specific, clinically significant reason why the member cannot use the brand formulation (brand formulation is preferred); and
- 4. For a diagnosis of acne vulgaris, the following must be met:
 - a. Member must be 20 years of age or younger; and
- 5. A quantity limit of 60 grams per 30 days will apply.

This is not a "grandfathered" category; members currently using Aczone[®] or Tazorac[®] will require submission of a prior authorization request after 12/4/2017. If a member requires Aczone[®] or Tazorac[®], prior authorization requests can be submitted for consideration to SoonerCare Pharmacy Services.

Updated versions of prior authorization criteria for Aczone[®] or Tazorac[®] can be downloaded from <u>www.okhca.org/rx-pa</u>, then clicking "Topical". Prior authorization request forms can be found online at <u>www.okhca.org/forms</u> (PHARM-4).

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SoonerCare Pharmacy Services • Pharmacy Management Consultants • PO Box 26901; ORI W-4403 • Oklahoma City, Oklahoma 73126-0901 • Phone: (800) 522-0114, option 4 • Fax: (800) 224-4014